Chronic Gvhd Clinical Trials
Here are the 6 most popular medical studies for chronic gvhd
Janus Kinase Inhibitor
Itacitinib for Graft-versus-Host Disease Prevention
This trial is testing whether a drug that inhibits Janus kinase 1 (JAK1) can help reduce graft-versus-host-disease (GVHD) and cytokine release syndrome (CRS) while still retaining the benefits of graft-versus-leukemia (GVL) and improving engraftment.
Monoclonal Antibodies
Tocilizumab for Graft-versus-Host Disease Prevention
This trial is testing whether the addition of the drug tocilizumab to the standard approach for GVHD prevention can reduce the risk of developing GVHD and GVHD-related complications. Tocilizumab works by blocking the effect of Interleukin-6, a protein that is elevated in the blood during periods of inflammation. This could potentially decrease the risk of developing GVHD and GVHD-associated complications.
Popular filter options for chronic gvhd trials
Graft-versus-Host Disease Clinical Trials
View 66 Graft-versus-Host Disease medical studies.
Janus Kinase Inhibitor
Ruxolitinib for Graft-versus-Host Disease
This trial will investigate the effects of a drug called ruxolitinib on children and adolescents with a certain type of medical condition. The trial will enroll around 42 subjects, and will look at the activity, safety, and how the body processes the drug in different age groups.
Immunosuppressive Agent
Nonmyeloablative Stem Cell Transplant for Sickle Cell Anemia and Thalassemia
This trial is testing a new variation of stem cell transplant that uses low dose radiation and a combination of immunosuppressive drugs to see if it helps the body better accept donor stem cells.
GVHD Clinical Trials
View 66 GVHD medical studies.
Janus Kinase Inhibitor
Ruxolitinib for Graft-versus-Host Disease
This trial will investigate the effects of a drug called ruxolitinib on children and adolescents with a certain type of medical condition. The trial will enroll around 42 subjects, and will look at the activity, safety, and how the body processes the drug in different age groups.
Immunosuppressive Agent
Nonmyeloablative Stem Cell Transplant for Sickle Cell Anemia and Thalassemia
This trial is testing a new variation of stem cell transplant that uses low dose radiation and a combination of immunosuppressive drugs to see if it helps the body better accept donor stem cells.
HLA Positive Clinical Trials
View 9 HLA positive medical studies.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
HLA-A Positive Clinical Trials
View 9 HLA-A positive medical studies.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Chronic Gvhd Clinical Trials With No Placebo
View 76 chronic gvhd medical studies that do not have a placebo group.
Janus Kinase Inhibitor
Ruxolitinib for Graft-versus-Host Disease
This trial will investigate the effects of a drug called ruxolitinib on children and adolescents with a certain type of medical condition. The trial will enroll around 42 subjects, and will look at the activity, safety, and how the body processes the drug in different age groups.
Immunosuppressive Agent
Nonmyeloablative Stem Cell Transplant for Sickle Cell Anemia and Thalassemia
This trial is testing a new variation of stem cell transplant that uses low dose radiation and a combination of immunosuppressive drugs to see if it helps the body better accept donor stem cells.
View More Chronic Gvhd Trials
See another 52 medical studies focused on chronic gvhd.
Frequently Asked Questions
Introduction to chronic gvhd
What are the top hospitals conducting chronic gvhd research?
When it comes to cutting-edge clinical trials in chronic graft-versus-host disease (GVHD), several hospitals are paving the way for advancements in treatment and management. Boston's Dana Farber Cancer Institute stands out with nine active trials focused on chronic GVHD, building upon their impressive history of 23 completed trials since initiating research in this area back in 2001. Not far behind, the Dana-Farber Cancer Institute, also located in Boston, is making significant strides with eight ongoing chronic GVHD trials and a total of 35 past studies dedicated to understanding this complex condition since their first trial recorded in 2000.
In the same city, Massachusetts General Hospital is actively contributing to research efforts as well. With eight ongoing clinical trials addressing chronic GVHD and a commendable record of 29 previously conducted studies dating back to their initial trial in 2001, they continue to expand our knowledge on effective treatments for this challenging condition.
Heading south to Bethesda, Maryland, we find the National Institutes of Health Clinical Center playing an important role as one of the leading institutions conducting active clinical trials related to chronic GVHD. Currently engaged in seven such studies and having pioneered investigations into chronic GVHD since as early as1996 when recording its first-ever trial on this particular issue.
Traveling across the country brings us to Seattle's Fred Hutchinson Cancer Research Center—a renowned hub for scientific breakthroughs—where researchers are currently exploring seven active clinical trials focused on finding innovative approaches for managing chronic GVHD. Their dedication extends beyond recent endeavors; they have been committed to studying this condition since successfully undertaking their inaugural trial all those years ago -1986- accumulating fifty-one groundbreaking studies along its course ever-since then
The commitment shown by these top hospitals underscores not only their dedication but also serves as a beacon of hope for patients battling against the challenges posed by chronic graft-versus-host disease. Through continued research and exploration within these esteemed medical centers, we move closer to improved treatments and enhanced quality of life for individuals affected by this condition globally.
Which are the best cities for chronic gvhd clinical trials?
When it comes to chronic graft-versus-host disease (cGVHD) clinical trials, several cities stand out as leaders in research and development. Boston, Massachusetts leads the way with 42 active trials focusing on treatments like Abatacept, Interleukin-2, and Cohort A: Belumosudil + Standard of Care Medications. New york, New York follows closely behind with 23 ongoing studies exploring options such as Ibrutinib and Alpha-1 antitrypsin (AAT). Duarte, California also showcases its commitment to cGVHD research with 21 active trials investigating interventions like Ibrutinib and Belumosudil (KD025). Seattle, Washington and Atlanta, Georgia round out the top five cities for cGVHD clinical trials. These cities offer individuals grappling with this complex condition access to cutting-edge research that holds promise for improved outcomes and quality of life.
Which are the top treatments for chronic gvhd being explored in clinical trials?
When it comes to exploring new treatments for chronic graft-versus-host disease (cGVHD), several contenders have emerged in recent clinical trials. Leading the pack is ibrutinib, currently involved in five active trials and having been listed as a potential treatment since 2013. Another promising option being explored is abatacept, with three ongoing trials and seven all-time cGVHD studies since its introduction in 2013. Additionally, cyclophosphamide has shown promise with three active trials and an impressive track record of 30 all-time cGVHD studies dating back to 2007. Ruxolitinib also deserves attention, participating in three current trials after first appearing on the scene in 2016 and accumulating a total of fourteen all-time cGVHD research endeavors. As researchers delve deeper into these investigations, they offer renewed hope to patients battling this challenging condition.
What are the most recent clinical trials for chronic gvhd?
Promising advancements in the treatment of chronic graft-versus-host disease (cGVHD) have emerged from recent clinical trials. A Phase 2 trial investigated the efficacy of a CD34+ peripheral blood progenitor cell transplant combined with a busulfan/melphalan/fludarabine regimen, offering potential breakthroughs for cGVHD management. Additionally, another Phase 2 trial explored graft-versus-host disease prophylaxis specifically targeted towards cGVHD prevention. Steroid therapy has also been under examination as an intervention for cGVHD, with both Phase 1 and Phase 2 trials demonstrating its potential benefits. These significant developments present new possibilities to alleviate the burden experienced by individuals affected by chronic GVHD and pave the way towards improved treatment strategies.
What chronic gvhd clinical trials were recently completed?
Recently concluded clinical trials have made significant strides in the study of chronic graft-versus-host disease (cGVHD), a debilitating condition that can occur after stem cell transplantation. Noteworthy completed trials include dexamethasone 0.5mg/5ml solution in Mucoloxâ„¢, conducted by the University of California, San Francisco in December 2020; Efmarodocokin Alfa, sponsored by Genentech, Inc., finished in November 2020; and Baricitinib from Washington University School of Medicine, which concluded its trial in April 2020. These investigations represent important advancements in understanding and potentially addressing cGVHD for the benefit of patients grappling with this challenging condition.